Literature DB >> 16446426

Activation of anti-hepatitis C virus responses via Toll-like receptor 7.

Jongdae Lee1, Christina C N Wu, Ki Jeong Lee, Tsung-Hsien Chuang, Kyoko Katakura, Yu-Tsueng Liu, Michael Chan, Rommel Tawatao, Michelle Chung, Carol Shen, Howard B Cottam, Michael M C Lai, Eyal Raz, Dennis A Carson.   

Abstract

IFN-alpha is used to suppress the replication of hepatitis C virus (HCV) in chronically infected patients with partial success. Here we present evidence showing that a ligand of Toll-like receptor 7 (TLR7) can induce anti-HCV immunity not only by IFN induction, but also through an IFN-independent mechanism. Human hepatocyte line Huh-7 carrying an HCV replicon expressed TLR7, and activation of the receptor induced several antiviral genes including IFN regulatory factor-7. Inhibitors of the enzyme inosine monophosphate dehydrogenase augmented both IFN-dependent and -independent antiviral effect. Prolonged exposure of Huh-7 cells to a TLR7 ligand [SM360320 (9-benzyl-8-hydroxy-2-(2-methoxyethoxy)adenine)], alone or in combination with an inosine monophosphate dehydrogenase inhibitor, reduced HCV levels dose dependently. Immunohistochemical analysis of livers shows that TLR7 is expressed in hepatocytes of normal or HCV-infected people. Because TLR7 agonists can impede HCV infection both via type I IFN and independently of IFN, they may be considered as an alternative treatment of chronic HCV infection, especially in IFN-alpha-resistant patients.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16446426      PMCID: PMC1413670          DOI: 10.1073/pnas.0510801103

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  38 in total

1.  Interferon-alpha induction through Toll-like receptors involves a direct interaction of IRF7 with MyD88 and TRAF6.

Authors:  Taro Kawai; Shintaro Sato; Ken J Ishii; Cevayir Coban; Hiroaki Hemmi; Masahiro Yamamoto; Kenta Terai; Michiyuki Matsuda; Jun-ichiro Inoue; Satoshi Uematsu; Osamu Takeuchi; Shizuo Akira
Journal:  Nat Immunol       Date:  2004-09-07       Impact factor: 25.606

2.  Broad-spectrum in vivo antiviral activity of 7-thia-8-oxoguanosine, a novel immunopotentiating agent.

Authors:  D F Smee; H A Alaghamandan; H B Cottam; B S Sharma; W B Jolley; R K Robins
Journal:  Antimicrob Agents Chemother       Date:  1989-09       Impact factor: 5.191

3.  Immune evasion by hepatitis C virus NS3/4A protease-mediated cleavage of the Toll-like receptor 3 adaptor protein TRIF.

Authors:  Kui Li; Eileen Foy; Josephine C Ferreon; Mitsuyasu Nakamura; Allan C M Ferreon; Masanori Ikeda; Stuart C Ray; Michael Gale; Stanley M Lemon
Journal:  Proc Natl Acad Sci U S A       Date:  2005-02-14       Impact factor: 11.205

4.  Toll-like receptor 9-induced type I IFN protects mice from experimental colitis.

Authors:  Kyoko Katakura; Jongdae Lee; Daniel Rachmilewitz; Gloria Li; Lars Eckmann; Eyal Raz
Journal:  J Clin Invest       Date:  2005-03       Impact factor: 14.808

5.  IRF-7 is the master regulator of type-I interferon-dependent immune responses.

Authors:  Kenya Honda; Hideyuki Yanai; Hideo Negishi; Masataka Asagiri; Mitsuharu Sato; Tatsuaki Mizutani; Naoya Shimada; Yusuke Ohba; Akinori Takaoka; Nobuaki Yoshida; Tadatsugu Taniguchi
Journal:  Nature       Date:  2005-03-30       Impact factor: 49.962

6.  Synthetic TLR agonists reveal functional differences between human TLR7 and TLR8.

Authors:  Keith B Gorden; Kevin S Gorski; Sheila J Gibson; Ross M Kedl; William C Kieper; Xiaohong Qiu; Mark A Tomai; Sefik S Alkan; John P Vasilakos
Journal:  J Immunol       Date:  2005-02-01       Impact factor: 5.422

7.  Thiazolo[4,5-d]pyrimidine nucleosides. The synthesis of certain 3-beta-D-ribofuranosylthiazolo[4,5-d]pyrimidines as potential immunotherapeutic agents.

Authors:  K Nagahara; J D Anderson; G D Kini; N K Dalley; S B Larson; D F Smee; A Jin; B S Sharma; W B Jolley; R K Robins
Journal:  J Med Chem       Date:  1990-01       Impact factor: 7.446

8.  Interferon regulatory factor-3 is an in vivo target of DNA-PK.

Authors:  Alla Y Karpova; Maren Trost; John M Murray; Lewis C Cantley; Peter M Howley
Journal:  Proc Natl Acad Sci U S A       Date:  2002-02-26       Impact factor: 11.205

9.  Enhanced expression of type I interferon and toll-like receptor-3 in primary biliary cirrhosis.

Authors:  Yasushi Takii; Minoru Nakamura; Masahiro Ito; Terufumi Yokoyama; Atsumasa Komori; Yuki Shimizu-Yoshida; Rumiko Nakao; Koichiro Kusumoto; Shinya Nagaoka; Koji Yano; Seigo Abiru; Toshihito Ueki; Takehiro Matsumoto; Manabu Daikoku; Ken Taniguchi; Hikaru Fujioka; Kiyoshi Migita; Hiroshi Yatsuhashi; Masahiro Nakashima; Mine Harada; Hiromi Ishibashi
Journal:  Lab Invest       Date:  2005-07       Impact factor: 5.662

10.  Hepatitis C virus infection activates the immunologic (type II) isoform of nitric oxide synthase and thereby enhances DNA damage and mutations of cellular genes.

Authors:  Keigo Machida; Kevin T-H Cheng; Vicky M-H Sung; Ki Jeong Lee; Alexandra M Levine; Michael M C Lai
Journal:  J Virol       Date:  2004-08       Impact factor: 5.103

View more
  67 in total

Review 1.  Induction and evasion of innate antiviral responses by hepatitis C virus.

Authors:  Stanley M Lemon
Journal:  J Biol Chem       Date:  2010-05-10       Impact factor: 5.157

2.  Phosphorylation of RIG-I by casein kinase II inhibits its antiviral response.

Authors:  Zhiguo Sun; Hongwei Ren; Yan Liu; Jessica L Teeling; Jun Gu
Journal:  J Virol       Date:  2010-11-10       Impact factor: 5.103

3.  Additive melanoma suppression with intralesional phospholipid-conjugated TLR7 agonists and systemic IL-2.

Authors:  Tomoko Hayashi; Michael Chan; John T Norton; Christina C N Wu; Shiyin Yao; Howard B Cottam; Rommel I Tawatao; Maripat Corr; Dennis A Carson; Gregory A Daniels
Journal:  Melanoma Res       Date:  2011-02       Impact factor: 3.599

4.  Regulation of human placental drug transporters in HCV infection and their influence on direct acting antiviral medications.

Authors:  Emily Pfeifer; Jessica Parrott; Gene T Lee; Ericka Domalakes; Helen Zhou; Lily He; Clifford W Mason
Journal:  Placenta       Date:  2018-07-10       Impact factor: 3.481

Review 5.  New and experimental therapies for HCV.

Authors:  Arema A Pereira; Ira M Jacobson
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2009-07       Impact factor: 46.802

6.  Diprovocims: A New and Exceptionally Potent Class of Toll-like Receptor Agonists.

Authors:  Matthew D Morin; Ying Wang; Brian T Jones; Yuto Mifune; Lijing Su; Hexin Shi; Eva Marie Y Moresco; Hong Zhang; Bruce Beutler; Dale L Boger
Journal:  J Am Chem Soc       Date:  2018-10-16       Impact factor: 15.419

7.  Phospholipidation of TLR7/8-active imidazoquinolines using a tandem phosphoramidite method.

Authors:  Hélène G Bazin; Laura S Bess; Mark T Livesay; Sandra C Mwakwari; David A Johnson
Journal:  Tetrahedron Lett       Date:  2016-04-01       Impact factor: 2.415

8.  Impaired toll-like receptor 3-mediated immune responses from macrophages of patients chronically infected with hepatitis C virus.

Authors:  Feng Qian; Christopher R Bolen; Chunxia Jing; Xiaomei Wang; Wei Zheng; Hongyu Zhao; Erol Fikrig; R Douglas Bruce; Steven H Kleinstein; Ruth R Montgomery
Journal:  Clin Vaccine Immunol       Date:  2012-12-05

Review 9.  Interaction of hepatitis C virus with the type I interferon system.

Authors:  Friedemann Weber
Journal:  World J Gastroenterol       Date:  2007-09-28       Impact factor: 5.742

10.  Prevention of autoimmune disease by induction of tolerance to Toll-like receptor 7.

Authors:  Tomoko Hayashi; Christine S Gray; Michael Chan; Rommel I Tawatao; Lisa Ronacher; Maureen A McGargill; Sandip K Datta; Dennis A Carson; Maripat Corr
Journal:  Proc Natl Acad Sci U S A       Date:  2009-02-02       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.